Table 1.
Summary of patients and mutations in miRNome per cancer type within the Pan-Cancer cohort.
| TCGA project (cancer type) | Full TCGA project name | No. of samples without (and with) hypermutated samples | No. (%) of samples with at least one mutation in miRNome | No. of mutated miRNA genes | No. of mutations | No. (%) of substitutions | No. (%) of insertions | No. (%) of deletions |
|---|---|---|---|---|---|---|---|---|
| ACC | Adrenocortical carcinoma | 92 (92) | 29 (31.5) | 49 | 63 | 55 (87.3) | 3 (4.8) | 5 (7.9) |
| BLCA | Bladder Urothelial Carcinoma | 411 (412) | 194 (47.2) | 283 | 372 | 354 (95.2) | 5 (1.3) | 13 (3.5) |
| BRCA | Breast invasive carcinoma | 1040 (1044) | 272 (26.1) | 297 | 415 | 371 (89.4) | 16 (3.9) | 28 (6.7) |
| CESC | Cervical squamous cell carcinoma and endocervical adenocarcinoma | 304 (305) | 132 (43.4) | 251 | 299 | 277 (92.6) | 6 (2.0) | 16 (5.4) |
| CHOL | Cholangiocarcinoma | 44 (44) | 12 (27.3) | 27 | 29 | 22 (75.9) | 0 (0.0) | 7 (24.1) |
| COAD | Colon adenocarcinoma | 411 (432) | 202 (49.1) | 390 | 604 | 482 (79.8) | 21 (3.5) | 101 (16.7) |
| DLBC | Lymphoid Neoplasm Diffuse Large B-cell Lymphoma | 37 (37) | 22 (59.5) | 22 | 36 | 35 (97.2) | 1 (2.8) | 0 (0.0) |
| ESCA | Esophageal carcinoma | 181 (182) | 99 (54.7) | 158 | 190 | 178 (93.7) | 0 (0.0) | 12 (6.3) |
| GBM | Glioblastoma multiforme | 394 (396) | 125 (31.7) | 207 | 269 | 246 (91.4) | 12 (4.5) | 11 (4.1) |
| HNSC | Head and Neck Squamous Cell Carcinoma | 510 (510) | 153 (30.0) | 199 | 248 | 228 (91.9) | 7 (2.8) | 13 (5.2) |
| KICH | Kidney Chromophobe | 66 (66) | 8 (12.1) | 6 | 10 | 9 (90.0) | 1 (10.0) | 0 (0.0) |
| KIRC | Kidney renal clear cell carcinoma | 339 (339) | 65 (19.2) | 85 | 95 | 81 (85.3) | 6 (6.3) | 8 (8.4) |
| KIRP | Kidney renal papillary cell carcinoma | 288 (288) | 62 (21.5) | 78 | 85 | 73 (85.9) | 5 (5.9) | 7 (8.2) |
| LAML | Acute Myeloid Leukemia | 149 (149) | 23 (15.4) | 36 | 39 | 33 (84.6) | 5 (12.8) | 1 (2.6) |
| LGG | Brain Lower Grade Glioma | 512 (513) | 62 (12.1) | 69 | 77 | 69 (89.6) | 3 (3.9) | 5 (6.5) |
| LIHC | Liver Hepatocellular Carcinoma | 375 (375) | 146 (38.9) | 172 | 214 | 198 (92.5) | 7 (3.3) | 9 (4.2) |
| LUAD | Lung adenocarcinoma | 567 (569) | 271 (47.8) | 356 | 561 | 536 (95.5) | 8 (1.4) | 17 (3.0) |
| LUSC | Lung squamous cell carcinoma | 497 (497) | 285 (57.3) | 365 | 576 | 554 (96.2) | 9 (1.6) | 13 (2.3) |
| MESO | Mesothelioma | 82 (82) | 20 (24.4) | 38 | 41 | 36 (87.8) | 0 (0.0) | 5 (12.2) |
| OV | Ovarian serous cystadenocarcinoma | 443 (443) | 162 (36.6) | 191 | 274 | 243 (88.7) | 18 (6.6) | 13 (4.7) |
| PAAD | Pancreatic adenocarcinoma | 182 (183) | 29 (15.9) | 30 | 36 | 34 (94.4) | 2 (5.6) | 0 (0.0) |
| PCPG | Pheochromocytoma and Paraganglioma | 164 (164) | 14 (8.5) | 15 | 15 | 15 (100.0) | 0 (0.0) | 0 (0.0) |
| PRAD | Prostate adenocarcinoma | 497 (498) | 39 (7.8) | 48 | 50 | 47 (94.0) | 0 (0.0) | 3 (6.0) |
| READ | Rectum adenocarcinoma | 146 (150) | 55 (37.7) | 69 | 83 | 77 (92.8) | 4 (4.8) | 2 (2.4) |
| SARC | Sarcoma | 240 (240) | 71 (29.6) | 98 | 120 | 112 (93.3) | 3 (2.5) | 5 (4.2) |
| SKCM | Skin Cutaneous Melanoma | 460 (470) | 298 (64.8) | 453 | 925 | 912 (98.6) | 7 (0.8) | 6 (0.6) |
| STAD | Stomach adenocarcinoma | 435 (441) | 195 (44.8) | 327 | 528 | 396 (75.0) | 16 (3.0) | 116 (22.0) |
| TGCT | Testicular Germ Cell Tumors | 150 (150) | 20 (13.3) | 19 | 22 | 21 (95.5) | 0 (0.0) | 1 (4.5) |
| THCA | Thyroid carcinoma | 495 (496) | 20 (4.0) | 20 | 21 | 19 (90.5) | 1 (4.8) | 1 (4.8) |
| THYM | Thymoma | 123 (123) | 19 (15.4) | 20 | 32 | 26 (81.2) | 1 (3.1) | 5 (15.6) |
| UCEC | Uterine Corpus Endometrial Carcinoma | 485 (542) | 242 (49.9) | 469 | 746 | 541 (72.5) | 31 (4.2) | 174 (23.3) |
| UCS | Uterine Carcinosarcoma | 56 (57) | 13 (23.2) | 18 | 19 | 17 (89.5) | 0 (0.0) | 2 (10.5) |
| UVM | Uveal Melanoma | 80 (80) | 11 (13.7) | 14 | 16 | 15 (93.8) | 0 (0.0) | 1 (6.2) |
| Pan-Cancer | - | 10255 (10369) | 3370 (32.9) | 1179 | 7110 | 6312 (88.8) | 198 (2.8) | 600 (8.4) |